Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus.
It is not known whether early immunosuppressive treatment can preserve long-term endogenous insulin secretion in subjects with insulin-dependent diabetes mellitus. In the present study, clinical remissions during the first year and C-peptide production for 3 years were followed after 43 subjects with newly diagnosed insulin-dependent diabetes mellitus were randomly assigned to a cyclosporine A treatment group for 4 months or to a control group. Of the six cyclosporine A-treated subjects who had remissions, five were 19 years of age or younger, compared with two of the four in the control group. C-peptide production was present in 98% of all subjects after 4 months, in 88% after 1 year, and in 43% after 3 years. There were no significant differences in numbers of subjects with C-peptide production or in mean hemoglobin A1 levels, between cyclosporine A-treated and control subjects after 3 years. Cyclosporine A treatment of subjects with newly diagnosed insulin-dependent diabetes mellitus for a period of 4 months does not have the ability to preserve residual beta-cell function.
Chase
H P
HP
Department of Pediatrics, University of Colorado Health Sciences Center, Denver 80262.
Butler-Simon
N
N
Garg
S K
SK
Hayward
A
A
Klingensmith
G J
GJ
Hamman
R F
RF
O'Brien
D
D
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002096:C-Peptide / Q000378:metabolism; D002648:Child; D003524:Cyclosporins / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D011897:Random Allocation
D002096:C-Peptide; D003524:Cyclosporins; D006442:Glycated Hemoglobin